These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 27294875)

  • 21. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
    Siliciano JD; Siliciano RF
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broad activation of latent HIV-1 in vivo.
    Barton K; Hiener B; Winckelmann A; Rasmussen TA; Shao W; Byth K; Lanfear R; Solomon A; McMahon J; Harrington S; Buzon M; Lichterfeld M; Denton PW; Olesen R; Østergaard L; Tolstrup M; Lewin SR; Søgaard OS; Palmer S
    Nat Commun; 2016 Sep; 7():12731. PubMed ID: 27605062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral latency and potential eradication of HIV-1.
    Matreyek KA; Oztop I; Freed EO; Engelman A
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):855-7. PubMed ID: 23030323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site.
    Hashemi FB; Barreto K; Bernhard W; Hashemi P; Lomness A; Sadowski I
    J Virol; 2016 Jun; 90(11):5302-14. PubMed ID: 26984732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.
    Ramakrishnan R; Liu H; Rice AP
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):137-41. PubMed ID: 24528253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.
    Edelstein LC; Micheva-Viteva S; Phelan BD; Dougherty JP
    AIDS Res Hum Retroviruses; 2009 Sep; 25(9):883-7. PubMed ID: 19689202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
    Wang FX; Xu Y; Sullivan J; Souder E; Argyris EG; Acheampong EA; Fisher J; Sierra M; Thomson MM; Najera R; Frank I; Kulkosky J; Pomerantz RJ; Nunnari G
    J Clin Invest; 2005 Jan; 115(1):128-37. PubMed ID: 15630452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.
    Doyon G; Sobolewski MD; Huber K; McMahon D; Mellors JW; Sluis-Cremer N
    PLoS One; 2014; 9(1):e84964. PubMed ID: 24489654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
    Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
    Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.
    Shan L; Deng K; Shroff NS; Durand CM; Rabi SA; Yang HC; Zhang H; Margolick JB; Blankson JN; Siliciano RF
    Immunity; 2012 Mar; 36(3):491-501. PubMed ID: 22406268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
    Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
    EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the Latent Reservoir for HIV-1.
    Sengupta S; Siliciano RF
    Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.